Deramiocel not checked

Capricor Inc. · CAP-1002

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
7 in total
Targets
—
None known yet

What this is

How it works
A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
How it’s given
“Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months”In the company’s words, NCT04428476 on ClinicalTrials.gov
Tested for
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases and 1 more
Main trialPhase 3
“HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional…”In the company’s words, NCT05126758 on ClinicalTrials.gov
Other names
Allogeneic Cardiosphere-Derived Cells · CAP-1002 · CDCs · Cardiosphere-Derived Cells

Other drugs for Muscular Dystrophies

All 44 drugs for Muscular Dystrophies

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 18 Jun 2025 A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Phase 2Active, not recruiting 16 Feb 2022 Open-label Extension of the HOPE-2 Trial
Phase 2Completed 14 Sep 2017 HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)
Phase 2Completed 6 Mar 2019 Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)
Phase 2Completed 10 Mar 2020 A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Phase 2Completed 4 Feb 2022 Intravenous Infusion of CAP-1002 in Patients With COVID-19
Phase 1/2Terminated 3 Jul 2017 Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Deramiocel

Following is part of Solo: you see every change to Deramiocel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in